Medicare drug coverage
Farxiga: 2027 Medicare Part D coverage
5,495 of 5,495 Part D plans (100%) list Farxiga on their 2027 formulary, up 42 points from 2026. 98% of those require prior authorization, step therapy, or a quantity limit.
License. US government work, Public Domain Mark 1.0.
2027 compared with 2026
Farxiga is number 8 by total Medicare Part D spending in 2024 ($5.3 billion). Plans that list it most often put it on tier 3. Counts use 3 RxNorm products for this name.
| Measure | 2026 | 2027 | Change |
|---|---|---|---|
| Part D plans in the file | 5,518 | 5,495 | -23 |
| Plans that list it | 3,174 (58%) | 5,495 (100%) | +42 points |
| Prior authorization (of plans that list it) | 0 (0%) | 961 (17%) | +17 points |
| Step therapy (of plans that list it) | 0 (0%) | 1,786 (33%) | +33 points |
| Quantity limit (of plans that list it) | 3,125 (98%) | 5,355 (97%) | -1 point |
| Any of the three (of plans that list it) | 3,125 (98%) | 5,361 (98%) | -1 point |
| Not listed or restricted (of all plans) | 5,469 (99%) | 5,361 (98%) | -2 points |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Formulary tier
| Tier | 2026 plans | 2027 plans |
|---|---|---|
| Tier 1 | 50 (2%) | 123 (2%) |
| Tier 2 | 38 (1%) | 305 (6%) |
| Tier 3 | 3,059 (96%) | 5,038 (92%) |
| Tier 4 | 0 (0%) | 13 (0%) |
| Tier 5 | 9 (0%) | 8 (0%) |
| Tier 6 | 18 (1%) | 8 (0%) |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Plan by plan, 2026 to 2027
4,380 plan ids are in both files. 1,095 of them (25%) added prior authorization, step therapy, or a quantity limit for Farxiga, and 0 stopped listing it.
| Plan by plan | Plans |
|---|---|
| Same plan id in both years | 4,380 |
| Listed it in 2026, not in 2027 | 0 (0%) |
| Listed it in 2027, not in 2026 | 1,829 (42%) |
| Moved it to a higher tier | 19 (0%) |
| Added prior authorization | 799 (18%) |
| Added step therapy | 296 (7%) |
| Added a quantity limit | 19 (0%) |
| Added at least one of the three | 1,095 (25%) |
| Removed at least one of the three | 0 (0%) |
| Plan ids new in 2027 | 1,115 |
| 2026 plan ids not in the 2027 file | 1,138 |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
States from most to least restrictive
Share of 2027 Part D plans offered in each state that leave Farxiga off the formulary or list it with prior authorization, step therapy, or a quantity limit. Montana ranks first at 100%, with 96% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.
| Rank | State | 2027 plans | Not listed or restricted | Prior auth or step therapy | Change from 2026 |
|---|---|---|---|---|---|
| 1 | Montana | 27 | 100% | 96% | no change |
| 2 | Wyoming | 13 | 100% | 92% | no change |
| 3 | Alaska | 9 | 100% | 89% | no change |
| 4 | Vermont | 14 | 100% | 86% | no change |
| 5 | North Dakota | 26 | 100% | 85% | no change |
| 6 | Idaho | 45 | 100% | 84% | no change |
| 7 | New Hampshire | 25 | 100% | 76% | no change |
| 8 | South Dakota | 30 | 100% | 73% | no change |
| 9 | New Mexico | 68 | 100% | 72% | no change |
| 10 | South Carolina | 91 | 100% | 70% | no change |
| 11 | Delaware | 43 | 100% | 70% | no change |
| 12 | Mississippi | 105 | 100% | 68% | no change |
| 13 | Michigan | 183 | 100% | 67% | no change |
| 14 | Maine | 52 | 100% | 65% | no change |
| 15 | Kentucky | 123 | 100% | 63% | no change |
| 16 | Utah | 53 | 100% | 62% | no change |
| 17 | Oklahoma | 81 | 100% | 62% | no change |
| 18 | Louisiana | 126 | 100% | 59% | no change |
| 19 | Rhode Island | 29 | 100% | 59% | no change |
| 20 | West Virginia | 70 | 100% | 57% | no change |
| 21 | Arkansas | 86 | 100% | 57% | no change |
| 22 | Nebraska | 51 | 100% | 57% | no change |
| 23 | Pennsylvania | 324 | 100% | 56% | no change |
| 24 | New Jersey | 74 | 100% | 55% | no change |
| 25 | North Carolina | 177 | 100% | 55% | no change |
| 26 | Texas | 412 | 100% | 52% | no change |
| 27 | Iowa | 64 | 100% | 52% | no change |
| 28 | Illinois | 133 | 100% | 51% | no change |
| 29 | Massachusetts | 92 | 100% | 51% | +23 points |
| 30 | Minnesota | 63 | 100% | 51% | no change |
| 31 | Arizona | 148 | 100% | 49% | no change |
| 32 | Alabama | 115 | 100% | 49% | no change |
| 33 | Ohio | 173 | 100% | 49% | no change |
| 34 | Kansas | 84 | 100% | 48% | no change |
| 35 | Missouri | 171 | 100% | 47% | no change |
| 36 | Indiana | 140 | 100% | 45% | no change |
| 37 | Connecticut | 54 | 100% | 43% | +4 points |
| 38 | Florida | 549 | 100% | 41% | no change |
| 39 | Tennessee | 157 | 100% | 40% | no change |
| 40 | Wisconsin | 97 | 99% | 66% | no change |
| 41 | Nevada | 100 | 97% | 50% | -3 points |
| 42 | Virginia | 145 | 96% | 62% | -4 points |
| 43 | Oregon | 92 | 96% | 39% | -4 points |
| 44 | Georgia | 151 | 95% | 63% | -5 points |
| 45 | New York | 215 | 90% | 33% | +1 point |
| 46 | Colorado | 106 | 90% | 48% | -10 points |
| 47 | Hawaii | 50 | 88% | 40% | -12 points |
| 48 | California | 397 | 88% | 45% | -12 points |
| 49 | Washington | 114 | 86% | 48% | -14 points |
| 50 | District of Columbia | 21 | 86% | 67% | -14 points |
| 51 | Maryland | 49 | 80% | 39% | -20 points |
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
By parent organization
164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Farxiga off or restrict it.
| Parent organization | 2027 plans ↓ | List it | Restrict it (of listing) | Not listed or restricted | Change from 2026 | Plans that added a restriction |
|---|---|---|---|---|---|---|
| Humana Inc. | 884 | 100% | 100% | 100% | no change | 799 |
| UnitedHealth Group, Inc. | 850 | 100% | 100% | 100% | no change | 0 |
| Devoted Health, Inc. | 728 | 100% | 100% | 100% | no change | 0 |
| CVS Health Corporation | 633 | 100% | 100% | 100% | no change | 0 |
| Elevance Health, Inc. | 294 | 100% | 100% | 100% | no change | 0 |
| Centene Corporation | 268 | 100% | 100% | 100% | no change | 0 |
| Health Care Service Corporation | 231 | 100% | 100% | 100% | no change | 166 |
| Kaiser Foundation Health Plan, Inc. | 112 | 100% | 0% | 0% | -100 points | 0 |
| Highmark Health | 98 | 100% | 100% | 100% | no change | 0 |
| SCAN Group | 85 | 100% | 100% | 100% | no change | 54 |
| Alignment Healthcare USA, LLC | 77 | 100% | 100% | 100% | no change | 0 |
| Guidewell Mutual Holding Corporation | 55 | 100% | 100% | 100% | no change | 0 |
| Blue Cross Blue Shield of Michigan Mutual Ins. Co. | 43 | 100% | 100% | 100% | no change | 0 |
| Molina Healthcare, Inc. | 43 | 100% | 100% | 100% | no change | 0 |
| Corewell Health | 40 | 100% | 100% | 100% | no change | 0 |
| Zing Health Consolidator, Inc | 36 | 100% | 100% | 100% | no change | 0 |
| CAPITAL BLUE CROSS | 35 | 100% | 100% | 100% | no change | 0 |
| Medica Holding Company | 31 | 100% | 100% | 100% | no change | 0 |
| UPMC Health System | 30 | 100% | 100% | 100% | no change | 0 |
| Universal Health Services, Inc. | 29 | 100% | 100% | 100% | no change | 0 |
| MHH Healthcare, L.P. | 26 | 100% | 100% | 100% | no change | 0 |
| Independence Health Group, Inc. | 25 | 100% | 100% | 100% | no change | 0 |
| Point32Health, Inc. | 23 | 100% | 100% | 100% | +100 points | 19 |
| BlueCross BlueShield of Tennessee | 22 | 100% | 100% | 100% | no change | 0 |
| California Physicians' Service | 22 | 100% | 100% | 100% | no change | 17 |
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Run it in Rivvi
Which 2027 plans near you dropped or restricted Farxiga?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Other Dapagliflozin Propanediol products
Near it by Part D spending
About this data
A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.
A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page